Access and download information and support tools for ADSTILADRIN

Patient Materials

Getting Started with ADSTILADRIN for Patients Downloadable Guide

Getting Started With ADSTILADRIN for Patients

This resource provides a patient-friendly overview of the ADSTILADRIN (nadofaragene firadenovec-vncg) clinical story as well as what patients should expect before and after treatment.


Practice Resources

ADSTILADRIN Clinical Overview Downloadable Guide

ADSTILADRIN Clinical Overview

This piece summarizes key information about ADSTILADRIN, including clinical data as well as dosing and support information.

ADSTILADRIN Instructions For Use Downloadable Guide

Instructions for Use

These instructions include an overview of storage, preparation, administration, and disposal information for ADSTILADRIN.

Product Acquisition Leave Behind Downloadable Guide

Product Acquisition Leave Behind

This leave behind provides a high-level product overview of ADSTILADRIN, including product codes.

Co-pay Assistance Program Eligibility Downloadable Guide

Co-Pay Assistance Program

Eligible, commercially insured patients may pay as little as $100 of their co-pay, coinsurance, or deductible. Visit for more details. Terms and conditions apply.

Verify eligibility

Reimbursement Form

Medicare Part B Reimbursement Downloadable Guide

Medicare Part B Reimbursement Guide

This piece provides information about Medicare Part B reimbursement.




Learn from Neal Shore, MD, FACS, a clinician from the ADSTILADRIN clinical trials, about ordering, storage, dosing, preparation, administration, and follow-up appointments.

Watch now

Hear From a Board-Certified Urologist

“In bladder oncology, I think that this represents a transformative breakthrough.”

Watch now
ADSTILADRIN® (nadofaragene firadenovec-vncg) Mechanism of Action video thumbnail

ADSTILADRIN Offers a Unique Way to Treat NMIBC

ADSTILADRIN is a gene therapy. It delivers the human interferon alpha 2B (IFNα2b) gene to bladder urothelial cells. It does not alter any existing genes in the body like some other gene therapies.

Watch now

Sign Up for Information

Sign up to receive information and updates on ADSTILADRIN

Your Information

Your Mailing Address

Interested in becoming a treatment site?*

*Required field.

Important Safety Information


ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.


CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.


  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

Close popup

Are you a US healthcare professional?

Supply Status

ADSTILADRIN supply information

We remain committed to ensuring widespread availability of ADSTILADRIN as early as possible and are therefore scaling up our manufacturing efforts to increase supply.

If you are interested in receiving supply updates, please sign up here.